Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Corradini P, et al. Among authors: zallio f. Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75. Blood. 2002. PMID: 11756155 Free article.
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.
Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P, Ladetto M, Podio V, Sargiotto A, Rossi G, Gianni AM, Pileri A. Tarella C, et al. Among authors: zallio f. Leukemia. 2001 Feb;15(2):256-63. doi: 10.1038/sj.leu.2402011. Leukemia. 2001. PMID: 11236941
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni AM, Tarella C. Ladetto M, et al. Among authors: zallio f. Leukemia. 2001 Dec;15(12):1941-9. doi: 10.1038/sj.leu.2402302. Leukemia. 2001. PMID: 11753616 Clinical Trial.
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.
Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, Gavarotti P, Marinone C, Pagano M, Rossi G, de Crescenzo A, Salomone A, Ladetto M, Boccadoro M, Pileri A. Tarella C, et al. Among authors: zallio f. Ann Hematol. 2001;80 Suppl 3:B123-6. doi: 10.1007/pl00022774. Ann Hematol. 2001. PMID: 11757693 Review. No abstract available.
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM. Tarella C, et al. Among authors: zallio f. Bone Marrow Transplant. 2002 Dec;30(11):725-32. doi: 10.1038/sj.bmt.1703729. Bone Marrow Transplant. 2002. PMID: 12439694 Clinical Trial.
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.
Cuttica A, Zallio F, Ladetto M, Di Nicola M, Caracciolo D, Magni M, Marinone C, Dell'Aquila M, Rosace M, Pileri A, Boccadoro M, Gianni AM, Tarella C. Cuttica A, et al. Among authors: zallio f. Cancer. 2003 Sep 1;98(5):983-92. doi: 10.1002/cncr.11610. Cancer. 2003. PMID: 12942566 Free article.
67 results